摘要
目的探讨益气活血中药复方通脉口服液对肾小管间质纤维化的干预作用。方法采用单侧输尿管结扎致肾小管间质纤维化模型,同时制备中医气虚血瘀模型,实验共分6组,分别为空白对照组、模型组、洛汀新组、通脉口服液高、中、低剂量组。观察实验大鼠用药前后证候积分、血清肌酐及尿素氮的水平、梗阻侧肾间质慢性病变（包括肾小管萎缩和间质纤维化）评分（atrophy and fibrosis score,AFS）、肾间质细胞浸润情况评分CIS（cell infiltration score,CIS）。结果通脉口服液可明显改善实验大鼠的症状,明显减轻肾组织纤维化的病理形态,降低纤维化指数,疗效优于洛汀新组。结论通脉口服液具有一定的抗肾小管间质纤维化作用。
Objective to discuss the intervention of the compound prescription of Tongmai oral suspension with the function of tonifying qi and promoting blood flow on renal tubulointerstitial fibrosis （TIF）.Methods Rat models with renal tubulointerstitial fibrosis （TIF） and Qi deficiency and blood stasis were made with unilateral ureteral occlusion （UUO）,and rat model of blood stasis due to qi deficiency was also made. The rats were randomized into six groups,i.e.,blank control group,model groups,the group administered with Lotensin,and the groups administered with Tongmai oral suspension at high,moderate,and low doses. Syndrome scoring,serum creatinine （SCR）,blood urea nitrogen （BUN）,and scoring of chronic pathological changes of renal interstitium including tubular atrophy and interstitial fibrosis,and scoring of interstitial cell infiltration were observed.Results Tongmai oral suspension could improve symptoms of rats in the experiment,significantly improving the pathomorphism of renal interstitial fibrosis,lowering tubulointerstitial fibrosis index （TFI）,with effects better than those of Lotensin.Conclusion Tongmai oral suspension could delay tubulointerstitial fibrosis.
出处
《广东药学院学报》
CAS
2010年第4期391-395,共5页
Academic Journal of Guangdong College of Pharmacy
基金
中国博士后基金(20070410818)
关键词
通脉口服液
益气活血
肾小管间质纤维化
Tongmai oral suspension
benefiting vital energy to promot blood circulation
renal tubulointerstitial fibrosis （TIF）
